The Importance of PDL1 in Breast Cancer

Most of my patients that are 90% PDL1 will receive monotherapy. With monotherapy, single agent, 30 to 40% of the patients progress in three months. You really have to take into account if your patient may allow a progression and still having a second chance. If there's nothing that looks active on scans anywhere, I'd probably take the risk and stop. But it would be a long conversation with the patient. And again, thinking back eight years ago, can you imagine presenting a case with three brain myths and a pathologic fracture that five years later, we'd be saying, should we stop therapy or not?"